Active Filter(s):
Details:
Under this agreement, Linical will provide strategic consulting services and regulatory guidance for Alpha-1062, a new chemical entity aimed to penetrate the Alzheimer's disease market.
Lead Product(s): Alpha-1062
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Undisclosed
Partner/Sponsor/Collaborator: Alpha Cognition
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership April 21, 2020